Project: A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours

Acronym MODIFY-NK (Reference Number: 11764)
Duration 01/04/2018
Project Topic The consortium will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a genetically non-identical donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project.
Network Eurostars 2
Call Eurostars Cut-Off 8

Project partner

Number Name Role Country
1 IPD Therapeutics BV (traded as Glycostem) Coordinator Netherlands
2 ImmuSmol SAS (traded as Explicyte Immuno-Oncology) Partner France
3 OZ Biosciences SAS Partner France
4 YUMAB GmbH Partner Germany